Long-term outcome of a self-help very-low-calorie-diet weight-loss program

1992 ◽  
Vol 56 (1) ◽  
pp. 279S-280S ◽  
Author(s):  
J S Cox ◽  
S N Kreitzman ◽  
A Y Coxon ◽  
J Walls
1999 ◽  
Vol 106 (2) ◽  
pp. 179-184 ◽  
Author(s):  
Marian Apfelbaum ◽  
Philippe Vague ◽  
Olivier Ziegler ◽  
Corinne Hanotin ◽  
Florence Thomas ◽  
...  

1999 ◽  
Vol 99 (4) ◽  
pp. 194c
Author(s):  
M Apfelbaum ◽  
P Vague ◽  
O Ziegler ◽  
C Hanotin ◽  
F Thomas ◽  
...  

2018 ◽  
Vol 29 (1) ◽  
pp. 54-60 ◽  
Author(s):  
Kamthorn Yolsuriyanwong ◽  
Komdej Thanavachirasin ◽  
Kimberly Sasso ◽  
Lauren Zuro ◽  
Jessica Bartfield ◽  
...  

BMJ Open ◽  
2019 ◽  
Vol 9 (11) ◽  
pp. e031431
Author(s):  
Simon Birk Kjær Jensen ◽  
Julie Rehné Lundgren ◽  
Charlotte Janus ◽  
Christian Rimer Juhl ◽  
Lisa Møller Olsen ◽  
...  

IntroductionThe success rate of weight loss maintenance is limited. Therefore, the purpose of this study is to investigate the maintenance of weight loss and immunometabolic health outcomes after diet-induced weight loss followed by 1-year treatment with a glucagon-like peptide-1 receptor agonist (liraglutide), physical exercise or the combination of both treatments as compared with placebo in individuals with obesity.Methods and analysisThis is an investigator-initiated, randomised, placebo-controlled, parallel group trial. We will enrol expectedly 200 women and men (age 18–65 years) with obesity (body mass index 32–43 kg/m2) to adhere to a very low-calorie diet (800 kcal/day) for 8 weeks in order to lose at least 5% of body weight. Subsequently, participants will be randomised in a 1:1:1:1 ratio to one of four study groups for 52 weeks: (1) placebo, (2) exercise 150 min/week+placebo, (3) liraglutide 3.0 mg/day and (4) exercise 150 min/week+liraglutide 3.0 mg/day. The primary endpoint is change in body weight from randomisation to end-of-treatment.Ethics and disseminationThe trial has been approved by the ethical committee of the Capital Region of Denmark and the Danish Medicines Agency. The trial will be conducted in agreement with the Declaration of Helsinki and monitored to follow the guidelines for good clinical practice. Results will be submitted for publication in international peer-reviewed scientific journals.Trial registration number2015-005585-32


Sign in / Sign up

Export Citation Format

Share Document